Amygdala Neurosciences

Amygdala Neurosciences is pioneering a novel pharmacological approach to treating addiction by targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme. Its lead asset, ANS-858, is an oral, reversible ALDH2 inhibitor in preclinical development with potential applications across multiple substance use disorders, starting with alcohol use disorder. The company is led by a seasoned management team with deep experience in founding, developing, and commercializing successful biotech ventures. Amygdala's strategy is based on the premise that ALDH2 inhibition can reduce cravings and relapse, addressing a significant unmet medical need in a large and underserved market.

Platform of selective, reversible small molecule inhibitors targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme to modulate brain reward pathways and reduce craving/relapse in addiction.

Competition includes approved drugs for AUD (naltrexone, acamprosate, disulfiram) and smoking cessation (varenicline, bupropion), as well as numerous biotech and pharma companies developing novel agents targeting opioid, nicotine, and stimulant use disorders. Amygdala's differentiation lies in its first-in-class oral ALDH2 inhibitor approach aimed directly at the craving mechanism, a target not broadly pursued by competitors.